Sleep Cycle (Q4 Review): 2026 – a year of investments for future growth - Redeye

Redeye has updated its estimates and valuation for Sleep Cycle following the Q4 2025 report. While the report was broadly in line with expectations, it confirmed a deliberate execution of the long-term strategy set in motion during 2024 as the company enters an "investment-heavy phase" in 2026 to capture growth in MedTech and B2B licensing/partnerships. On the back of the 2026 guidance, we have made significant downward adjustments to our near-term forecast, leading to a reduction in our Base Case.

Länk till analysen i sin helhet: https://www.redeye.se/research/1146643/sleep-cycle-q4-review-2026-a-year-of-investments-for-future-growth?utm_source=finwire&utm_medium=RSS